Benchmark offloads UK vaccine facility amid COVID-19 response

The sale comes as the UK government is scaling up infrastructure to support the manufacturing of human vaccines and therapeutics in the wake of COVID-19.

Trond Williksen, CEO of Benchmark, the aquaculture genetics firm. — Trond Williksen, CEO of Benchmark, the aquaculture genetics firm.Photo: Anders Furuset

Demi Korban

Published 23 July 2020, 10:45Updated 23 July 2020, 10:51

COVID-19 Benchmark Vaccines Genetics Trond Williksen